On 10 May 2010, the Australian biotechnology company Avexa, announced the closure of the development programme for the nucleoside apricitabine (AVX754).

According to an earlier statement in March, initial three-week results from the study suggest activity against HIV with M184V mutation, associated with high-level resistance to 3TC and FTC.

Apricitabine is a cytidine analogue similar to 3TC and 48-week results from Phase 2b studies were presented at the HIV Congress in Glasgoew in 2008. [2]

Avexa were developing apricitabine under license from Shire Pharmaceuticals.

References

1. Avexa Press Statement (10 May 2010).

http://www.avexa.com.au/freestyler/files/Avexa%20closes%20apricitabine%20program.pdf

2. Cahn P et al. 48-week data from Study AVX-201 – A randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance. Abstract O414.

http://www.jiasociety.org/content/11/S1/O41